Wegovy treatment may keep weight off for years
Patients taking Danish drugmarker Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight loss after four years, the drugmaker said, revealing its new longer-term data in May at the European Congress on Obesity in Venice, Italy.
"This is the longest study we've conducted so far of semaglutide for weight loss," said Martin Holst Lange, Ph.D., M.D., Novo's head of development, referring to the active ingredient in Wegovy and the company's diabetes drug Ozempic.
"We see that once the majority of the weight loss is accrued, you don't go back and start to increase in weight if you stay on the drug," he added.
Read more: Reuters
The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.